在三阴性乳腺癌细胞中,ProNGF通过TrkA/EphA2诱导的Src激活促进大脑转移
Julien Cicero1,2,3, Sarah Trouvilliez1,3, Martine Palma1,3
1UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Boulevard du Professeur Jules Leclercq, 59000, Lille, France.
Experimental hematology & oncology
|December 10, 2023
概括
神经生长因子 (proNGF) 的前体通过影响血脑屏障,驱动三阴性乳腺癌 (TNBC) 中的大脑转移. 准TrkA/EphA2复合体为TNBC大脑转移提供了一个潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 神经科学是一个神经科学.
- 癌症转移 癌症转移
背景情况:
- 三阴性乳腺癌 (TNBC) 是一种侵略性,脑转移严重影响患者的生存和生活质量.
- 驱动TNBC大脑转移的机制尚不清楚,需要进一步研究.
研究的目的:
- 阐明TNBC大脑转移背后的分子机制.
- 确定用于预防或治疗TNBC中大脑转移的新型治疗点.
主要方法:
- 使用了体外 (人体血脑屏障模型,3D器官类型矩阵) 和体外 (老鼠大脑切片) 模型的组合,以及体内异种移植实验.
- 研究了神经生长因子 (proNGF) 的前体及其信号通路在TNBC大脑转移中的作用.
主要成果:
- 证明了proNGF在TNBC大脑转移中的参与,独立于TrkA酸化.
- 确定了TrkA/EphA2信号复合体对于proNGF诱导的血脑屏障转移至关重要.
- 显示TrkA和EphA2的联合抑制在临床前模型中减少了TNBC大脑转移.
结论:
- proNGF是TNBC大脑转移的一个关键驱动因素.
- TrkA/EphA2信号复合体代表了TNBC大脑转移的一个有希望的治疗点.
相关概念视频
Enzyme-linked Receptors
78.5K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.5K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K


